Calculating Serious Infection Risk in IMID Patients

Save

Predictive modeling of data derived from the DANBIO registry (of treated IMID patients) revealed a 4 fold increased risk of serious infection (SIE) in those starting biologic DMARD (bDMARD) treatment. From this large dataset, researchers developed a simple prediction model to estimate future infection risk that may inform shared decision-making in individual patients.

JAK Inhibitor Misses Endpoint in Safety Study. Now What?

Save

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.

Mortality Risk in Rheumatoid Lung Patients

Save

A Medicare claims analysis of rheumatoid arthritis (RA) patients showed that RA-associated interstitial lung disease (RA-ILD) was seen in nearly 5% of patients and was found to increase mortality risks, including respiratory and cancer mortality not explained by other factors.

2020 Rheumatology Year in Review

Save

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.

The risk of RA was studied in cohort of 14,463 endometriosis pts. RA risk was higher in those w/ endometriosis [adjusted HR 1.75), and also w/ age ≥45 years (adj HR 1.50) or with autoimmune disease (adj HR 6.99). https://t.co/sPouzyFI3H https://t.co/lDjSgLxXfV